AI Summary
In a landmark cross-border healthcare agreement presented directly to Vietnam’s General Secretary and President To Lam and French President Emmanuel Macron, French pharmaceutical giant Sanofi and Vietnam Vaccine Joint Stock Company (VNVC) announced plans to manufacture three next-generation vaccines in Vietnam. Formalized in Paris during the Vietnam-France Business Forum, a gathering where both heads of state convened with corporate leaders to evaluate strategic cooperation across fields such as pharmaceuticals and healthcare, the two organizations exchanged a joint declaration in the presence of top French and Vietnamese officials. Under this pact, Vietnam will become the first country in Southeast Asia to manufacture three next-generation vaccines developed by France’s Sanofi under a new partnership with VNVC, prioritizing their production locally at VNVC’s Vaccine and Biologics Manufacturing Plant.
Product Portfolio, Timelines, and Regional Ambitions
The initial manufacturing roster targets essential public health solutions that address substantial domestic demand across several age demographics by guarding against severe, potentially fatal infectious conditions. Specifically, the rollout focuses on an acellular pertussis-containing six-in-one vaccine, a seasonal influenza vaccine, and a meningococcal vaccine. Highlighting the milestone, Ngo Chi Dung, chairman and chief executive of VNVC, said the agreement would make Vietnam the first country in Southeast Asia capable of independently producing these next-generation vaccines.
The current roadmap outlines the start of manufacturing operations in 2028, leading up to commercial distribution in 2029. Backed by initial output targeted at tens of millions of doses annually for local patients before scaling outward to regional territories and international supply networks, Dung noted his desire for continuous backing from both administrations to keep timelines on schedule and deliver superior immunizations at lower consumer costs.
Facility Footprint and Strategic Biotech Goals
Production will center at VNVC’s Vaccine and Biologics Manufacturing Plant in Tay Ninh Province, an installation spanning more than 26,000 square metres that represents a phase-one outlay exceeding VND 2.5 trillion (USD 96 million) and carries a projected output potential of roughly 120 million vaccine doses per year. Emphasizing the broader strategic alignment, Stephen Alix, head of international markets for Sanofi’s vaccine division, commended Vietnam’s policy framework supporting innovation, science and technology, high-tech sectors, and overall healthcare resilience.
“Through this project, Sanofi hopes to make a meaningful contribution to Vietnam’s national development goals and help build an increasingly modern biotechnology ecosystem in the country,” Alix said.
Ultimately, this venture mirrors Vietnam’s overarching drive to lessen its dependence on overseas medical imports, fortify domestic immunization self-sufficiency, and establish a footprint as an advanced biotechnology and pharmaceutical manufacturing hub.
